Presbyopia-correcting drops provide hope for frustrated patients
Dr Cathleen McCabe describes how VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.
Dr Cathleen McCabe sits down with Sheryl Stevenson of Ophthalmology Times Europe to discuss the recently FDA-approved drops, VUITY. At AAO 2021, her presentation entitled, "GEMINI 1 and 2 pooled Phase 3 safety and efficacy: AGN-190584 primary and key secondary endpoints," discussed the finer points of the clinical trial that led to VUITY's early approval.
Allergan, a subsidiary of AbbVie, announced on October 29, 2021, that the US Food and Drug Administration (FDA) has approved pilocarpine HCl Ophthalmic Solution 1.25% for the treatment of adult patients with presbyopia.
Pilocarpine HCl ophthalmic solution 1.25% is the first and only approved eye drop to treat age-related blurry near vision.
The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Centre in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.
Related Content: Additional AAO content | Cataract & Refractive | Retina
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
